FAR Overhaul: Implications for Psychedelic R&D Contracting in the U.S.

Federal Acquisition Regulation Overhaul: What Is Changing?

The Federal Acquisition Regulatory Council (FAR Council) has proposed a comprehensive overhaul of the Federal Acquisition Regulation (FAR), as announced in the Federal Register on September 18, 2026. The proposed rules target Parts 16, 17, and 35 of the FAR, which govern types of contracts, special contracting methods, and research and development (R&D) contracting, respectively. This initiative is in response to Executive Order 14275, which mandates the reduction of unnecessary acquisition regulations to enhance efficiency in federal procurement.

For the psychedelic research community, this marks the most significant proposed change to federal R&D contracting in over two decades. The overhaul aims to streamline application processes, reduce administrative burdens, and clarify compliance requirements for entities seeking federal research funding—including those in emerging fields such as psychedelic science.

Mechanisms: How the FAR Proposal Could Affect Psychedelic Research

The proposed revisions to FAR Parts 16, 17, and 35 could directly impact how federal agencies contract with academic, nonprofit, and private sector partners for psychedelic research. Specifically, the changes may:

• Shorten and simplify application and reporting requirements, potentially lowering the administrative threshold for smaller or newer organizations to compete for funding.
• Modify eligibility criteria or evaluation factors, which could alter the competitive landscape for both established and emerging psychedelic research entities.
• Standardize contract types and special contracting methods, possibly affecting how agencies structure agreements for early-stage, high-risk, or translational psychedelic science.

One non-obvious implication is that streamlined requirements could inadvertently disadvantage organizations that have invested heavily in compliance infrastructure, while benefiting newer entrants or smaller academic labs that previously faced prohibitive administrative costs. This could democratize access to federal psychedelic R&D funding, but may also introduce new risks if oversight mechanisms are weakened.

Policy and Research Implications for Psychedelic Science

The FAR overhaul could have far-reaching consequences for the psychedelic research ecosystem in the United States. If finalized as proposed, the rule changes may:

• Increase the number and diversity of applicants for federal psychedelic research contracts, potentially accelerating innovation and broadening the evidence base.
• Shift the balance of funding from well-established institutions to smaller or less traditional actors, including startups and community-based organizations.
• Change the compliance landscape, requiring researchers to adapt to new documentation, reporting, and audit standards.

For agencies such as the National Institutes of Health (NIH), Department of Defense (DoD), and National Aeronautics and Space Administration (NASA)—all of which have funded or expressed interest in psychedelic research—these changes could enable more flexible and responsive contracting. However, the final impact will depend on the specific language of the final rule and how agencies implement the revised FAR in practice.

Risks, Unknowns, and Stakeholder Considerations

While the intent is to streamline and modernize federal R&D contracting, several risks and uncertainties remain for the psychedelic research sector:

• The final rule text may differ substantially from the proposal, with potential for new compliance requirements or limitations not yet visible.
• Reduced administrative barriers may increase competition, but could also strain agency review capacity or dilute oversight of sensitive research areas such as psychedelics.
• Changes to contract types or evaluation criteria could unintentionally deprioritize high-risk, exploratory research in favor of projects with more predictable outcomes.

Stakeholders should also be aware that the FAR Council’s overhaul is part of a broader federal effort to modernize procurement, and psychedelic research is only one of many affected domains. Active engagement during the public comment period and close monitoring of subsequent agency guidance will be essential for those seeking to maintain or expand federal funding in this space.

Looking Ahead: Preparing for a New Federal R&D Landscape

The proposed FAR overhaul represents both an opportunity and a challenge for psychedelic research in the United States. If finalized, the changes could lower longstanding administrative barriers and open federal funding to a wider range of actors. However, the transition will require careful navigation of new rules, proactive compliance planning, and strategic engagement with federal agencies.

Researchers, institutions, and industry stakeholders should review the official Federal Register notice, assess their current contracting capabilities, and prepare to adapt to a potentially more dynamic—but also more competitive—federal funding environment for psychedelic science.

How we research: This article was written and reviewed by Dr. Alex Morrison, PhD (policy editor, Psychedelic Research Journal), on 2026-09-20. Primary source: Federal Register, Docket No. 2026-19160.